Regeneron Pharmaceuticals Stock Forward View - Triple Exponential Smoothing

Key Indicators . Triple Exponential Smoothing . Stocks . USA . 
Stock . Regeneron Pharmaceuticals
REGN Stock  USD 709.10  -11.95  -1.66%   
Regeneron Pharmaceuticals's Triple Exponential Smoothing forecast is computed from observed closing prices over the selected horizon. The accuracy statistics below distinguish a well-fitted model from one that is smoothing over meaningful price movement. The Triple Exponential Smoothing model projects Regeneron Pharmaceuticals at 712.36 for the next trading day, above the most recent closing price. The Triple Exponential Smoothing output reflects statistical model results and is provided for reference purposes.
Triple exponential smoothing (Holt-Winters method) for Regeneron Pharmaceuticals extends the double exponential model by adding a seasonality component. It simultaneously estimates the level, trend, and periodic pattern in Regeneron Pharmaceuticals price series.

Triple Exponential Smoothing Price Forecast For the 8th of May

Over a 90-day horizon, the Triple Exponential Smoothing model forecasts Regeneron Pharmaceuticals at 712.36 for the next trading day, with a mean absolute deviation of 12.37 , mean absolute percentage error of 0.02 , and sum of absolute errors of 730.01 .
This represents a very tight forecast — the model closely tracks Regeneron Pharmaceuticals' recent price behavior. This output is intended for short-term analytical reference.

Stock Forecast Pattern

Backtest Regeneron Pharmaceuticals  Regeneron Pharmaceuticals Price Prediction  Research Analysis  

Forecasted Value

Regeneron Pharmaceuticals' next-session forecast estimates practical downside and upside boundaries based on the model's historical fit. The projected band runs from roughly 710.50 on the downside to about 714.21 on the upside. The narrow range indicates limited short-term dispersion.
Market Value
709.10
710.50
Downside
712.36
Expected Value
714.21
Upside
Target Odds

Model Predictive Factors

The table below summarizes the Triple Exponential Smoothing model's error metrics for Regeneron Pharmaceuticals stock. Lower MAD and MAPE values indicate tighter forecast accuracy. AIC measures relative model quality — lower values indicate less information loss and a better-fitting model. A large Bias suggests systematic over- or under-prediction.
AICAkaike Information CriteriaHuge
BiasArithmetic mean of the errors 1.9569
MADMean absolute deviation12.373
MAPEMean absolute percentage error0.0164
SAESum of the absolute errors730.0088
This model is designed for Regeneron Pharmaceuticals price data that exhibits both a directional trend and recurring seasonal patterns. If the underlying series lacks seasonality, simpler models may produce tighter forecasts with fewer parameters. As with all exponential smoothing methods, recent observations carry the greatest weight in the forecast.

Other Forecasting Options for Regeneron Pharmaceuticals

Analyzing Regeneron Pharmaceuticals' price movement through moving averages at different time horizons reveals whether short-term momentum aligns with the longer-term trend. Touches of the upper or lower band in Regeneron Pharmaceuticals' chart signal overbought or oversold conditions.
Naive Prediction
Simple Exponential Smoothing
Double Exponential Smoothing
Triple Exponential Smoothing
Simple Regression
Polynomial Regression
Simple Moving Average
4 Period Moving Average
8 Period Moving Average
20 Period Moving Average

Regeneron Pharmaceuticals Related Equities

These stocks within the Health Care space are often compared to Regeneron Pharmaceuticals by analysts and fund managers in the sector. Peer review on balance sheet metrics shows how Regeneron Pharmaceuticals' capital structure stacks up against similar firms. Peer pricing is more meaningful when the firms compared share similar business models and end markets. These checks provide a starting point for deeper study of Regeneron Pharmaceuticals' strengths and weak spots.
 Risk & Return  Correlation

Regeneron Pharmaceuticals Market Strength Events

For investors tracking Regeneron Pharmaceuticals, market strength indicators offer quantitative evaluation of stock behavior. When Rate of Change diverges from price direction, it often signals weakening momentum before a visible reversal in Regeneron Pharmaceuticals.
Accumulation Distribution15058.63
Daily Balance Of Power-0.67
Rate Of Daily Change0.98
Day Median Price716.37
Day Typical Price713.95
Price Action Indicator-13.24
Period Momentum Indicator-11.95
Relative Strength Index43.96

Regeneron Pharmaceuticals Risk Indicators

Analyzing Regeneron Pharmaceuticals' basic risk indicators provides a structured view of the risk-return trade-off for regeneron stock. Expected shortfall estimates the average loss in the worst-case tail scenarios, going beyond what standard deviation alone captures for Regeneron Pharmaceuticals.
Mean Deviation1.45
Standard Deviation1.87
Variance3.5
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Regeneron Pharmaceuticals Short Properties

Short-interest signals around Regeneron Pharmaceuticals reveal whether skeptical positioning is starting to pressure price predictability and market tone. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
Common Stock Shares Outstanding108.6 million
Cash And Short Term Investments8.61 billion

More Resources for Regeneron Stock Analysis

A clear view of Regeneron Pharmaceuticals comes from reviewing its financial structure and trends. These indicators describe how financial results are generated.
Regeneron Risk and Volatility Profile
Details
Regeneron Stock Market Risk Analysis
Details
What is Regeneron Pharmaceuticals' Net Worth?
Details
Top Sectors
Directory
View
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.